Document is current
Any future updates will be listed below
-
Authors
Luttens, Andreas https://orcid.org/0000-0003-2915-7901
Vo, Duc Duy
Scaletti, Emma R.
Wiita, Elisée
Almlöf, Ingrid
Wallner, Olov
Davies, Jonathan
Košenina, Sara https://orcid.org/0000-0001-7893-0249
Meng, Liuzhen
Long, Maeve
Mortusewicz, Oliver https://orcid.org/0000-0002-4290-4994
Masuyer, Geoffrey https://orcid.org/0000-0002-9527-2310
Ballante, Flavio https://orcid.org/0000-0002-4831-3423
Michel, Maurice
Homan, Evert
Scobie, Martin
Kalderén, Christina
Warpman Berglund, Ulrika
Tarnovskiy, Andrii V.
Radchenko, Dmytro S. https://orcid.org/0000-0001-5444-7754
Moroz, Yurii S. https://orcid.org/0000-0001-6073-002X
Kihlberg, Jan https://orcid.org/0000-0002-4205-6040
Stenmark, Pål https://orcid.org/0000-0003-4777-3417
Helleday, Thomas
Carlsson, Jens https://orcid.org/0000-0003-4623-2977
- License Information
-
More Information
Article History
Received: 27 April 2024
Accepted: 28 January 2025
First Online: 18 February 2025
Competing interests
: J.C. is a founder of DareMe Drug Discovery Consulting. O.W. and T.H. are listed as inventors on U.S. patent no. WO2019166639 A1, covering a different class of OGG1 inhibitors than those described in this work. The patent is fully owned by a non-profit public foundation, the Helleday Foundation, and T.H. is a member of the foundation board. U.W.B., C.K. and M.S. are employees of Oxcia, a company developing OGG1 inhibitors towards the clinic. T.H. is a member of the board of Directors of Oxcia. D.S.R. and Y.S.M. are employed with Enamine Ltd. Y.S.M. serves as a scientific advisor to Chemspace LLC. The remaining authors declare no competing interests.
